This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
University of California, Davis
ClinicalTrials.gov Identifier:
NCT00389805
First received: October 18, 2006
Last updated: April 7, 2017
Last verified: April 2017
  Purpose

RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of two different schedules of bortezomib when given together with pemetrexed disodium and to see how well they work in treating patients with advanced non-small cell lung cancer or other solid tumors.


Condition Intervention Phase
Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific Drug: bortezomib Drug: pemetrexed disodium Genetic: gene expression analysis Genetic: mutation analysis Genetic: protein expression analysis Genetic: reverse transcriptase-polymerase chain reaction Other: flow cytometry Other: immunoenzyme technique Other: immunohistochemistry staining method Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Phase I/II Study of Two Different Schedules of Bortezomib (VELCADE, PS-341) and Pemetrexed (ALIMTA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:


Further study details as provided by University of California, Davis:

Primary Outcome Measures:
  • Number of Patients Experiencing a Dose-limiting Toxicity (Phase I) [ Time Frame: Up to 36 months ]
    Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion or lasting >7 days; febrile neutropenia; grade 3 neutropenia associated with infection; any other grade >/=3 non-hematologic toxicity considered by the investigator to be related to study drug.

  • Number of Participants Who Experience Adverse Events (Phase I) [ Time Frame: Throughout the entire study (up to 36 months). ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v3.0 (Phase I).

  • Number of Patients With Grade ≥ 3 Toxicity (Phase I) [ Time Frame: First cycle of treatment (3 weeks) ]
    Grade 3/4 toxicity occurring in a patient within 1 cycle.

  • Number of Patients Who Responded to Study Treatment (Phase II) [ Time Frame: From start of treatment until disease progression/recurrence. ]
    To determine the response rate of bortezomib in combination with pemetrexed in patients with advanced NSCLC. Response rate was assessed by CT scan. CT scans was performed at baseline and every two cycles (prior to 3rd and 5th cycle). The evaluation of response was based on standard RECIST criteria.


Secondary Outcome Measures:
  • Number of Patients With Toxicity by NCI CTC v3.0 (Phase I) [ Time Frame: Up to 36 months ]
    Adverse events possibly related to treatment, graded according to the NCI CTCAE v3.0.

  • Maximum Tolerated Dose of Bortezomib in Combination With Pemetrexel (Phase I) [ Time Frame: Up to 36 months ]
  • Treatment Efficacy as Measured by RECIST (Phase I) [ Time Frame: Up to 36 months ]
    Response to therapy was evaluated every 2 cycles according to RECIST criteria.

  • Number of Participants With Toxicities (Phase II) [ Time Frame: Up to 36 months ]
    Each adverse event will be determined by using the NCI CTCAE, Version 3.0.

  • Analysis of Molecular Determinants in Tumor Samples (Phase II) [ Time Frame: Up to 36 months ]
    Expression of relevant molecular targets of the proteasome, which is inhibited by bortezomib.

  • Importance of Folate-associated Gene Expression and Response or Outcome (Phase II) [ Time Frame: Up to 36 months ]
    Overexpression of reduced folate carrier (RFC) protein is thought to contribute to decreased resistance to pemetrexed. Levels of expression will be studied by measuring mRNA transcripts using quantitative Reverse Transcriptase-Polymerase Chain Reaction in archival patient tumor specimens.

  • Effect of Bortezomib on Over Expression of NF-kB, BCL-2, and BCL-xL (Phase II) [ Time Frame: Up to 36 months ]
    Tumor levels of BCL-2, BCL-xL and BAX will be assessed by immunohistochemistry (IHC).


Enrollment: 27
Study Start Date: March 2005
Study Completion Date: June 2007
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Cytologically or histologically confirmed diagnosis of 1 of the following:

    • Advanced solid tumor that progressed after standard therapy or for which no effective curative therapy exists (phase I)
    • Stage IIIB (pleural effusion) or IV non-small cell lung cancer (NSCLC) (phase II)

      • Disease must have progressed or recurred after 1 platinum-based therapy regimen
      • NSCLC that has progressed or recurred after first-line therapy for stage IIIA or IIIB disease allowed
  • Measurable disease

    • Disease in previously irradiated sites is considered measurable if there is clear disease progression following radiotherapy
    • Evaluable disease (bone metastases, pleural fluid, ascites) allowed (phase I)
  • No symptomatic brain metastasis or disease requiring steroids and anticonvulsants

    • Asymptomatic, previously treated (surgical resection or radiotherapy) brain metastases allowed provided patient is neurologically stable and has been off steroids and anticonvulsants for ≥ 4 weeks

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-2 (phase I) or 0-1 (phase II)
  • Life expectancy ≥ 3 months
  • Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min
  • Bilirubin normal
  • AST ≤ 2.5 times upper limit of normal
  • Granulocyte count ≥ 1,500/mm³
  • Platelet count of ≥ 100,000/mm³
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after completion of study treatment
  • No pre-existing neuropathy ≥ grade 2
  • No other prior malignancy except for the following (phase II):

    • Adequately treated basal cell or squamous cell skin cancer
    • In situ cervical cancer
    • Adequately treated stage I or II cancer currently in complete remission
    • Any other cancer from which the patient has been disease free for > 5 years
  • No hypersensitivity to bortezomib, boron, or mannitol
  • No cardiovascular complications, including any of the following:

    • Myocardial infarction within the past 6 months
    • New York Heart Association class III-IV heart failure
    • Uncontrolled angina
    • Severe uncontrolled ventricular arrhythmias
    • Electrocardiographic (ECG) evidence of acute ischemia or active conduction system abnormalities

      • Any ECG abnormality at screening must be documented as not medically relevant

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior bortezomib or pemetrexed disodium
  • Any number of prior chemotherapy regimens allowed (phase I)
  • More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C) and recovered
  • More than 2 weeks since prior radiotherapy and recovered
  • No nonsteroidal anti-inflammatory drugs (NSAIDs) or salicylates 2 days prior and 2 days after (5 days pre and post for long-acting NSAIDs) administration of pemetrexed disodium
  • No concurrent anticonvulsants that are metabolized by the cytochrome P450 pathway
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00389805

Locations
United States, California
University of California Davis Cancer Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
Eli Lilly and Company
Investigators
Study Chair: Angela Davies, MD University of California, Davis
  More Information

Publications:
Responsible Party: University of California, Davis
ClinicalTrials.gov Identifier: NCT00389805     History of Changes
Other Study ID Numbers: UCDCC#158
H3E-US-X038 ( Other Identifier: Eli Lilly )
Study First Received: October 18, 2006
Results First Received: January 20, 2017
Last Updated: April 7, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of California, Davis:
recurrent non-small cell lung cancer
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Bortezomib
Pemetrexed
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on June 28, 2017